Trial Profile
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Oct 2021
Price :
$35
*
At a glance
- Drugs Golimumab (Primary) ; Ustekinumab (Primary)
- Indications Sarcoidosis
- Focus Therapeutic Use
- Sponsors Centocor; Janssen
- 28 Oct 2014 New trial record